Rhythm Biosciences Limited (FRA:0RY)

Market Cap	16.67M
Revenue (ttm)	1.89M
Net Income (ttm)	-1.30M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	70
Open	0.0560
Previous Close	0.0715
Day's Range	0.0560 - 0.0560
52-Week Range	0.0270 - 0.0825
Beta	n/a
RSI	65.43
Earnings Date	Aug 29, 2025

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2017
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0RY

Financial Performance

In 2024, Rhythm Biosciences's revenue was 1.69 million, a decrease of -45.41% compared to the previous year's 3.10 million. Losses were -6.86 million, -16.56% less than in 2023.

Financial numbers in AUD